Abiopharma

🔍 Cox Andrew (Executive)

Company: FORRESTER RESEARCH, INC. (FORR)

Report Date: 2026-06-01

Detailed Transactions and Holdings:

• Acquired 4,264 shares of Common Stock (Direct)
  Date: 2026-06-01 | Code: M | equity_swap_involved: false | shares_owned_after: 7,041.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,568 shares of Common Stock at $7.22 per share (Direct)
  Date: 2026-06-01 | Code: F | equity_swap_involved: false | shares_owned_after: 5,473.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 4,264 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-01 | Code: M | equity_swap_involved: false | shares_owned_after: 12,792.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4

Footnotes:

• F1: Represents the conversion, upon vesting, of restricted stock units into common stock.
• F2: Represents shares withheld by the Issuer to satisfy tax withholding obligations upon the vesting on June 1, 2026 of the restricted stock units awarded to the reporting person on June 2, 2025. The awards include a provision for the withholding of shares by the Issuer to satisfy withholding taxes due as a result of the vesting of the awards.
• F3: Each Restricted Stock Unit represents the right to receive, following vesting, one share of Forrester Research, Inc. common stock.
• F4: On June 2, 2025, the reporting person was granted 17,056 Restricted Stock Units that vest and convert into common stock in four equal and consecutive installments on June 1, 2026, June 1, 2027, June 1, 2028 and June 1, 2029.